Skip to content
Propoxyphene napsylate
Darvocet A500, Darvocet-n, Darvon-n, Propacet (propoxyphene napsylate) is a small molecule pharmaceutical. Propoxyphene napsylate was first approved as Darvocet-n 50 on 1982-01-01. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetaminophen
+
Propoxyphene napsylate
Tradename
Company
Number
Date
Products
DARVOCET-N 50Xanodyne PharmaceuticalsN-017122 DISCN1982-01-01
1 products
DARVOCET-N 100Xanodyne PharmaceuticalsN-017122 DISCN1982-01-01
1 products
Hide discontinued
Aspirin
+
Propoxyphene napsylate
Tradename
Company
Number
Date
Products
DARVON-N W/ ASAAAIPharmaN-016829 DISCN1982-01-01
1 products
DARVON-N W/ ASAAAIPharmaN-016863 DISCN1982-01-01
1 products
Hide discontinued
Propoxyphene napsylate
Tradename
Company
Number
Date
Products
DARVON-NAAIPharmaN-016861 DISCN1982-01-01
1 products
DARVON-NXanodyne PharmaceuticalsN-016862 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
darvon-nNew Drug Application2009-10-27
propoxyphene napsylate and acetaminophenANDA2011-06-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AC: Diphenylpropylamine derivative analgesics
— N02AC04: Dextropropoxyphene
— N02AC54: Dextropropoxyphene, combinations excl. psycholeptics
— N02AC74: Dextropropoxyphene, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80———1—1
PainD010146EFO_0003843R52———1—1
Healthy volunteers/patients————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePROPOXYPHENE NAPSYLATE
INNdextropropoxyphene
Description
Dextropropoxyphene is the (1S,2R)-(+)-diastereoisomer of propoxyphene. It has a role as an opioid analgesic and a mu-opioid receptor agonist. It is an enantiomer of a levopropoxyphene.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1
Identifiers
PDB—
CAS-ID469-62-5
RxCUI8785
ChEMBL IDCHEMBL3989716
ChEBI ID—
PubChem CID10100
DrugBankDB00647
UNII IDS2F83W92TK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,204 documents
View more details
Safety
Black-box Warning
Black-box warning for: Darvon-n
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9,861 adverse events reported
View more details